For Researchers

If my muscle could talk: Myokines as a biomarker of frailty

H.J. Coelho-Junior, A. Picca, R. Calvani, et al.

Exp Gerontol. 2019 Aug 29:110715. doi: 10.1016/j.exger.2019.110715. [Epub ahead of print]

This review discusses the rationale to support the use of myokines as biomarkers of frailty in older adults.

Associations of fat-soluble micronutrients and redox biomarkers with frailty status in the FRAILOMIC initiative

B. Kochlik, W. Stuetz, K. Pérès, et al.

J Cachexia Sarcopenia Muscle. 2019 Aug 21. doi: 10.1002/jcsm.12479. [Epub ahead of print]

A poor fat-soluble micronutrient (FMN) and a high oxidative stress status are associated with frailty. Our aim was to determine the cross-sectional association of FMNs and oxidative stress biomarkers [protein carbonyls (PrCarb) and 3-nitrotyrosine] with the frailty status in participants older than 65 years.

Efficacy of Nutritional Interventions as Stand-Alone or Synergistic Treatments with Exercise for the Management of Sarcopenia

S. Damanti, D. Azzolino, C. Roncaglione, et al.

Nutrients. 2019;11(9)

At present, the only strategies for the management of sarcopenia are mainly based on nutritional and physical exercise interventions. The purpose of this review is to provide an overview on the role of proteins and other key nutrients, alone or in combination with physical exercise, on muscle parameters.

The Role of Muscle Mass Gain Following Protein Supplementation Plus Exercise Therapy in Older Adults with Sarcopenia and Frailty Risks: A Systematic Review and Meta-Regression Analysis of Randomized Trials

C.D. Liao, H.C. Chen, S.W. Huang, et al.

Nutrients. 2019;11(8). pii: E1713. doi: 10.3390/nu11081713.

Aging and frailty are associated with a high risk of lean mass (LM) loss, which leads to physical disability and can be effectively alleviated by protein supplementation (PS) and muscle strengthening exercise (MSE). In this study, the associations between LM gain and PS + MSE efficacy (measured using physical outcomes) in elderly patients with a high risk of sarcopenia or frailty were identified.

Medium-chain triglycerides (8:0 and 10:0) are promising nutrients for sarcopenia: a randomized controlled trial

S. Abe, O. Ezaki, M. Suzuki

Am J Clin Nutr. 2019 Jul 23. pii: nqz138. doi: 10.1093/ajcn/nqz138. [Epub ahead of print]

The combined supplementation of medium-chain triglycerides (MCTs), l-leucine-rich amino acids, and cholecalciferol was previously shown to increase muscle strength and function in frail elderly individuals.

We examined whether treatment with MCTs alone is sufficient to increase muscle strength and function and activities of daily living (ADL) in such individuals.

Associations of Plasma 3-Methylhistidine with Frailty Status in French Cohorts of the FRAILOMIC Initiative

B. Kochlik, W. Stuetz, K. Pérès, et al.

J Clin Med. 2019 Jul 10;8(7). pii: E1010. doi: 10.3390/jcm8071010.

Plasma 3-methylhistidine (3-MH), as well as the 3-MH-to-creatinine (3-MH/Crea) and 3-MH-to-estimated glomerular filtration rate (3-MH/eGFR) ratios might support the diagnosis of frailty. Therefore, we investigated the cross-sectional associations between plasma 3-MH, 3-MH/Crea and 3-MH/eGFR with the frailty status of community-dwelling individuals (>65 years).

Pages